An obesity medication from Viking Therapeutics succeeded in a Phase 2 clinical study, the company said Tuesday, helping patients lose up to nearly 15% of their weight over about three months and further fueling the competition in the exploding obesity drug market.
Shares of the San Diego-based company doubled in premarket trading.
The trial tested four different weekly injectable doses of the Viking drug, called VK2735, over 13 weeks, with patients seeing a dose-dependent amount of weight loss over the period. Those on the highest dose — 15 milligrams — lost 14.7% of weight.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.statnews.com/2024/02/27/obesity-viking-therapeutics-phase-2/?utm_campaign=rss